These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

848 related articles for article (PubMed ID: 29674797)

  • 41. Estimation of adverse drug reaction reporting in Iran: Correction for underreporting.
    Khalili M; Mesgarpour B; Sharifi H; Golozar A; Haghdoost AA
    Pharmacoepidemiol Drug Saf; 2021 Aug; 30(8):1101-1114. PubMed ID: 33772938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
    Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
    Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug safety alerts of pharmacovigilance programme of India: A scope for targeted spontaneous reporting in India.
    Thota P; Thota A; Medhi B; Sidhu S; Kumar P; Selvan VK; Singh GN
    Perspect Clin Res; 2018; 9(1):51-55. PubMed ID: 29430420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports.
    Leitzen S; Dubrall D; Toni I; Stingl J; Christ P; Köberle U; Schmid M; Neubert A; Sachs B
    Paediatr Drugs; 2023 Mar; 25(2):203-215. PubMed ID: 36369590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Time series analysis of using the PDCA method combined with the Teach-back method to improve spontaneous reports of adverse drug reactions in a grade IIIA hospital in China.
    Li B; Jiang L; Liao L; Chen Y; Xu Z; Wu N; Chen H; Wu P; Liu T
    Eur J Clin Pharmacol; 2024 Mar; 80(3):383-393. PubMed ID: 38151504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
    Inácio P; Airaksinen M; Cavaco A
    Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inter-rater agreement between WHO- Uppsala Monitoring Centre system and Naranjo algorithm for causality assessment of adverse drug reactions.
    More SA; Atal S; Mishra PS
    J Pharmacol Toxicol Methods; 2024; 127():107514. PubMed ID: 38768933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Knowledge creation about adverse drug reactions in the paediatric population].
    Aagaard L
    Ugeskr Laeger; 2013 Feb; 175(6):342-5. PubMed ID: 23402239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
    Svendsen K; Wood M; Olsson E; Nordeng H
    Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
    Masuka JT; Khoza S
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adverse drug reactions experience in a teaching hospital in Jordan.
    Alsbou M; Alzubiedi S; Alzobi H; Samhadanah NA; Alsaraireh Y; Alrawashdeh O; Aqel A; Al-Salem K
    Int J Clin Pharm; 2015 Dec; 37(6):1188-93. PubMed ID: 26286340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adverse drug reactions profile of antimicrobials: A 3-year experience, from a tertiary care teaching hospital of India.
    ; Tandon VR; Sharma S; Khajuria V; Mahajan V; Gillani Z
    Indian J Med Microbiol; 2015; 33(3):393-400. PubMed ID: 26068342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
    Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
    Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New guideline for tramadol usage following adverse drug reactions reported to the Iranian Pharmacovigilance Center.
    Gholami K; Shalviri G; Zarbakhsh A; Daryabari N; Yousefian S
    Pharmacoepidemiol Drug Saf; 2007 Feb; 16(2):229-37. PubMed ID: 17063533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 'Have we missed reporting adverse drug reactions under Revised National TB Control Programme?' - A mixed method study in Bengaluru, India.
    Krishnappa L; Gadicherla S; Chidambaram P; Anuradha HV; Somanna SN; Naik PR; Das A; Narasimhaiah S; Nagaraja SB
    Indian J Tuberc; 2020 Jan; 67(1):20-28. PubMed ID: 32192612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Pharmacovigilance of parenterally administered salvianolate based on analysis of spontaneous reporting system data].
    Lu PF; Xiang YY; Xie YM; Chang YP; Wang ZG
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3003-7. PubMed ID: 24471320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
    Geer MI; Koul PA; Tanki SA; Shah MY
    J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
    Yang W; Xiang YY; Xie YM; Shen H
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Under-reporting of adverse drug reactions, a problem that also involves medicines subject to additional monitoring. Preliminary data from a single-center experience on novel oral anticoagulants].
    Patrignani A; Palmieri G; Ciampani N; Moretti V; Mariani A; Racca L
    G Ital Cardiol (Rome); 2018 Jan; 19(1):54-61. PubMed ID: 29451510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.